Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl-dependent mechanisms

Wenbin Xu, Wei Wei, Qing Yu, Chao Wu, Chenjing Ye, Yingli Wu, Hua YanMolecular 2014 · DOI

Abstract

Arsenic trioxide ($As_2O_3$) and the proteasome inhibitor bortezomib (BTZ) have been used successfully to treat acute promyelocytic leukemia and multiple myeloma. In this study, interactions between $As_2O_3$ and BTZ were examined in imatinib-resistant Bcr/Abl+ (K562r) cells. Co-treatment with subtoxic concentrations of $As_2O_3$ (2 µM) and BTZ (24 nM) resulted in a synergistic enhancement in growth inhibition and apoptosis. These events were associated with activation of protein kinase Cδ, poly ADP-ribose polymerase cleavage, and caspase-3 activation, along with downregulation of Bcr/Abl mRNA and protein expression levels. These findings suggest that BTZ and $As_2O_3$ act synergistically to induce apoptosis in K562r cells, offering a potential combinatory treatment for chronic myeloid leukemia.

Introduction

Chronic Myelogenous Leukemia (CML) is driven by the Bcr/Abl fusion protein, a constitutively active tyrosine kinase that promotes cell survival and proliferation. While imatinib mesylate (Gleevec) revolutionized CML treatment, many patients develop resistance, often by maintaining Bcr/Abl signaling despite inhibition. This study investigates whether a combination of two established anticancer agents—arsenic trioxide and bortezomib—can overcome this resistance by synergistically targeting the Bcr/Abl pathway.

Figure 3: Western blot analysis showing the dose-dependent downregulation of Bcr/Abl protein by imatinib in sensitive CML models, illustrating the protein's role as a primary therapeutic target.

Methods

The researchers utilized K562 (imatinib-sensitive) and K562r (imatinib-resistant) human CML cell lines. Cell viability was measured using CCK-8 assays, while apoptosis was quantified via Annexin V staining and flow cytometry. Molecular mechanisms were explored through Western blotting for Bcr/Abl, cleaved Caspase-3, PARP, and PKCδ. Additionally, qPCR was used to measure Bcr/Abl mRNA levels, and fluorescent probes were employed to detect changes in Reactive Oxygen Species (ROS).

Results

Synergistic Efficacy at Subtoxic Doses

A critical finding of the study is that $As_2O_3$ and BTZ exhibit potent synergy at low, clinically achievable doses. When used individually at subtoxic levels (2 µM $As_2O_3$ and 24 nM BTZ), the drugs had minimal effect on K562r cells. However, their combination resulted in a dramatic increase in both growth inhibition and the induction of programmed cell death.

Figure 4: Comprehensive analysis of $As_2O_3$ and BTZ effects on K562r cells. (A, B) Dose-response growth curves for $As_2O_3$ and BTZ. (C) Synergistic growth inhibition by the combination treatment at 24 and 48 hours. (D) Synergistic induction of apoptosis by the combination treatment.

Molecular Mechanism of Action

Unlike imatinib, which primarily inhibits Bcr/Abl kinase activity, the $As_2O_3$/BTZ combination was found to downregulate the expression of Bcr/Abl at both the mRNA and protein levels. This depletion of the survival-driving oncoprotein was accompanied by the activation of the apoptotic machinery, including the cleavage of PARP and Caspase-3, and the activation of PKCδ. Interestingly, ROS levels were downregulated during the combination treatment, suggesting a unique disruption of Bcr/Abl-mediated survival signaling.

Discussion

This study demonstrates that the synergistic interaction between $As_2O_3$ and BTZ can effectively overcome imatinib resistance in CML cells. By reducing the total abundance of the Bcr/Abl protein and activating internal apoptotic pathways, this dual-agent approach offers a promising therapeutic strategy. These results provide a strong rationale for further in vivo studies and potential clinical evaluation of this combination for patients with multi-drug resistant CML.

Summary updated

Abstract

Arsenic trioxide (As2O3) and the proteasome inhibitor bortezomib (BTZ) have been used successfully to treat acute promyelocytic leukemia and multiple myeloma. Their synergistic effects with other anticancer drugs have been widely studied. In this study, interactions between As2O3 and BTZ were examined in imatinib‑resistant Bcr/Abl+ (K562r) cells. Co‑treatment of K562r cells with subtoxic concentrations of As2O3 (2 µM) and BTZ (24 nM) resulted in a synergistic enhancement in growth inhibition and apoptosis, as demonstrated by increased annexin V staining. These events were associated with activation of protein kinase Cδ, poly ADP‑ribose polymerase cleavage and caspase‑3 activation, along with downregulation of Bcr/Abl mRNA and Bcr/Abl protein expression levels during apoptosis. In addition, reactive oxygen species were downregulated during combined treatment in K562r cells. Collectively, these findings suggest that BTZ and As2O3 act synergistically to induce apoptosis in K562r cells. Therefore, further studies are required to assess the potential of BTZ and As2O3 combinatory treatment of chronic myeloid leukemia, particularly using imatinib‑resistant Bcr/Abl+ clones.
BibTeX
@inproceedings{xu2014arsenic,
  author = {Wenbin Xu and Wei Wei and Qing Yu and Chao Wu and Chenjing Ye and Yingli Wu and Hua Yan},
  title = {{Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl-dependent mechanisms}},
  booktitle = {Molecular},
  year = {2014},
  doi = {10.3892/mmr.2014.2333},
}
Figure